Aspira Women's Health Inc. – NASDAQ:AWH
Aspira Women's Health stock price today
Aspira Women's Health stock price monthly change
Aspira Women's Health stock price quarterly change
Aspira Women's Health stock price yearly change
Aspira Women's Health key metrics
Market Cap | 12.01M |
Enterprise value | 35.69M |
P/E | -1.72 |
EV/Sales | 2.93 |
EV/EBITDA | -0.80 |
Price/Sales | 3.80 |
Price/Book | 6.86 |
PEG ratio | -0.09 |
EPS | -1.45 |
Revenue | 8.99M |
EBITDA | -18.15M |
Income | -14.74M |
Revenue Q/Q | -7.03% |
Revenue Y/Y | 4.46% |
Profit margin | -367.96% |
Oper. margin | -413.67% |
Gross margin | 51.44% |
EBIT margin | -413.67% |
EBITDA margin | -201.94% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAspira Women's Health stock price history
Aspira Women's Health stock forecast
Aspira Women's Health financial statements
| Jun 2023 | 2.49M | -2.31M | -93.01% |
|---|---|---|---|
| Sep 2023 | 2.21M | -4.70M | -212.27% |
| Dec 2023 | 2.13M | -3.08M | -145.02% |
| Mar 2024 | 2.15M | -4.62M | -215% |
| Mar 2024 | 2.15M | -4.62M | -215% |
|---|---|---|---|
| Sep 2025 | 3.38M | -2.22M | -65.79% |
| Oct 2025 | 4.85M | -2.01M | -41.52% |
| Dec 2025 | 5.45M | -1.83M | -33.69% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 7720000 | 8.24M | 106.84% |
|---|---|---|---|
| Sep 2023 | 8662000 | 9.32M | 107.61% |
| Dec 2023 | 6262000 | 8.62M | 137.77% |
| Mar 2024 | 7164000 | 8.52M | 119.03% |
| Jun 2023 | -3.41M | -4K | 134K |
|---|---|---|---|
| Sep 2023 | -3.32M | 0 | 4.17M |
| Dec 2023 | -3.45M | -12K | 961K |
| Mar 2024 | -4.43M | -20K | 5.26M |
Aspira Women's Health alternative data
| Aug 2023 | 85 |
|---|---|
| Sep 2023 | 85 |
| Oct 2023 | 85 |
| Nov 2023 | 85 |
| Dec 2023 | 85 |
| Jan 2024 | 85 |
| Feb 2024 | 85 |
| Mar 2024 | 85 |
| Apr 2024 | 85 |
| May 2024 | 64 |
| Jun 2024 | 64 |
| Jul 2024 | 64 |
Aspira Women's Health other data
| Period | Buy | Sel |
|---|---|---|
| Sep 2023 | 2246 | 0 |
| Dec 2023 | 5000 | 980 |
| Jan 2024 | 4800 | 0 |
| May 2024 | 9493 | 0 |
| Jul 2024 | 13072 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | RAGARD JOHN PHILLIP director | Restricted Stock Units | 4,844 | N/A | N/A | ||
Option | VOS ELLEN O'CONNOR director | Common Stock | 5,313 | N/A | N/A | ||
Option | VOS ELLEN O'CONNOR director | Restricted Stock Units | 5,313 | N/A | N/A | ||
Option | CAVANAUGH STEFANIE L. director | Common Stock | 5,938 | N/A | N/A | ||
Option | CAVANAUGH STEFANIE L. director | Restricted Stock Units | 5,938 | N/A | N/A | ||
Option | PARNELL WINFRED director | Common Stock | 5,156 | N/A | N/A | ||
Option | PARNELL WINFRED director | Restricted Stock Units | 5,156 | N/A | N/A | ||
Option | HERCHUK JANNIE PRESTRIDGE director | Common Stock | 8,438 | N/A | N/A | ||
Option | HERCHUK JANNIE PRESTRIDGE director | Restricted Stock Units | 8,438 | N/A | N/A | ||
Option | RAGARD JOHN PHILLIP director | Common Stock | 4,844 | N/A | N/A |
| Patent |
|---|
Application Filling date: 13 Aug 2019 Issue date: 15 Jul 2021 |
Application Filling date: 14 Dec 2020 Issue date: 17 Jun 2021 |
| Quarter | Transcript |
|---|---|
| Q1 2024 15 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 28 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 13 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 14 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Ms. Valerie Barber Palmieri (1961) Chief Executive Officer, Pres & Director | $600,680 |
Mr. Robert Harry Beechey CPA (1963) Chief Financial Officer | $392,680 |
-
What's the price of Aspira Women's Health stock today?
One share of Aspira Women's Health stock can currently be purchased for approximately $0.08.
-
When is Aspira Women's Health's next earnings date?
Unfortunately, Aspira Women's Health's (AWH) next earnings date is currently unknown.
-
Does Aspira Women's Health pay dividends?
No, Aspira Women's Health does not pay dividends.
-
How much money does Aspira Women's Health make?
Aspira Women's Health has a market capitalization of 12.01M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 11.85% to 9.15M US dollars.
-
What is Aspira Women's Health's stock symbol?
Aspira Women's Health Inc. is traded on the NASDAQ under the ticker symbol "AWH".
-
What is Aspira Women's Health's primary industry?
Company operates in the Healthcare sector and Medical - Diagnostics & Research industry.
-
How do i buy shares of Aspira Women's Health?
Shares of Aspira Women's Health can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Aspira Women's Health's key executives?
Aspira Women's Health's management team includes the following people:
- Ms. Valerie Barber Palmieri Chief Executive Officer, Pres & Director(age: 64, pay: $600,680)
- Mr. Robert Harry Beechey CPA Chief Financial Officer(age: 62, pay: $392,680)
-
How many employees does Aspira Women's Health have?
As Jul 2024, Aspira Women's Health employs 64 workers, which is 25% less then previous quarter.
-
When Aspira Women's Health went public?
Aspira Women's Health Inc. is publicly traded company for more then 24 years since IPO on 2 Oct 2000.
-
What is Aspira Women's Health's official website?
The official website for Aspira Women's Health is aspirawh.com.
-
Where are Aspira Women's Health's headquarters?
Aspira Women's Health is headquartered at Building III, Austin, TX.
-
How can i contact Aspira Women's Health?
Aspira Women's Health's mailing address is Building III, Austin, TX and company can be reached via phone at +51 25190400.
Aspira Women's Health company profile:
Aspira Women's Health Inc.
aspirawh.comNASDAQ
64
Medical - Diagnostics & Research
Healthcare
Aspira Women's Health Inc., together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company provides OVA1, OVERA, and OVA1plus to detect risk of ovarian malignancy in women with adnexal masses. It also offers ASPiRA GenetiX, a genetic test for the risk of gynecologic cancer. In addition, the company operates Aspira Synergy, a testing platform and cloud service for decentralized access of protein biomarker and hereditary genetic testing; and owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. Further, its pipeline products include OVAWatch, EndoCheck, and OVAInherit. The company serves physicians, physician office laboratories, and national and regional laboratories. It has a collaborative research agreement with Baylor Genetics; an agreement with Harvard Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University Lodz to evaluate the microRNA technology in combination with Aspira technologies for the development of an early detection test for ovarian cancer; and a strategic alliance with Quest Diagnostics, Incorporated. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is headquartered in Austin, Texas.
Austin, TX 78738
CIK: 0000926617
ISIN: US04537Y2081
CUSIP: 04537Y109
